Company news
Biocon Limited (NSE:BIOCON) news
Biocon Limited news releases on 6ix. Latest, Sep 21, 2026: Biocon Limited Press Release Sep 21 2026
Press releases & updates
Biocon Limited Press Release Sep 21 2026
September 20, 2026
Biocon Limited Press Release Sep 08 2026
September 7, 2026
Biocon Announces Supplemental U.S. FDA Approval For Prefilled Autoinjector For YESINTEK
September 2, 2026
Biocon Launches Aflibercept Biosimilar In The United States
August 24, 2026
Biocon Limited Press Release Aug 05 2026
August 5, 2026
Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg
August 3, 2026
Biocon Limited Press Release Aug 03 2026
August 2, 2026
Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili, a Biosimilar to Eylea
July 10, 2026
Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)
July 9, 2026
Biocon Limited Press Release Jul 09 2026
July 8, 2026
Biocon Limited Press Release Jun 24 2026
June 23, 2026
Press Release May 07 2026
May 7, 2026
Press Release Apr 21 2026
April 21, 2026
Biocon Receives Health Canada Approval of Bosaya™ (Denosumab) and Vevzuo™ (Denosumab), Biosimilars to Prolia® and Xgeva®
April 21, 2026
Biocon Limited Press Release Apr 21 2026
April 20, 2026
Press Release Apr 07 2026
April 7, 2026
Shreehas Tambe Appointed CEO and Managing Director of Biocon Limited, Effective April 1, 2026
March 30, 2026
Press Release Mar 27 2026
March 27, 2026
Press Release Feb 24 2026
February 24, 2026
Press Release Feb 12 2026
February 12, 2026
Press Release Feb 07 2026
February 7, 2026
Press Release Jan 28 2026
January 28, 2026
Biocon Limited Press Release Jan 28 2026
January 27, 2026
Press Release Jan 15 2026
January 15, 2026
Biocon Limited Press Release Jan 15 2026
January 14, 2026
Press Release Jan 06 2026
January 6, 2026
Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference
January 6, 2026
Press Release Dec 23 2025
December 23, 2025
Biocon Limited Press Release Dec 23 2025
December 22, 2025
Press Release Dec 17 2025
December 17, 2025
Biocon Limited Press Release Dec 17 2025
December 16, 2025
Press Release Dec 15 2025
December 15, 2025
Biocon Limited Press Release Dec 15 2025
December 14, 2025
Press Release Dec 13 2025
December 13, 2025
Press Release Dec 11 2025
December 11, 2025
Press Release Dec 06 2025
December 6, 2025
Biocon Limited Press Release Dec 06 2025
December 5, 2025
Press Release Dec 02 2025
December 2, 2025
Biocon Limited Press Release Dec 02 2025
December 1, 2025
Press Release Nov 11 2025
November 11, 2025
Press Release Oct 23 2025
October 23, 2025
Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®
October 23, 2025
Biocon Limited Press Release Oct 23 2025
October 22, 2025
Press Release Oct 16 2025
October 16, 2025
Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options
October 16, 2025
Press Release Oct 01 2025
October 1, 2025
Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
October 1, 2025
Biocon Limited Press Release Oct 01 2025
September 30, 2025
Press Release Sep 18 2025
September 18, 2025
Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases
September 18, 2025